Sugi Predict

Sugi Predict / Compounds / SCHEMBL507554

SCHEMBL507554

SCHEMBL507554

N#Cc1ccc2nc(Br)sc2c1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 3/20 0.56
▸ DYRK1A Q13627 1/20 0.54
▸ CSNK1D P48730 1/20 0.49
▸ CSNK1G2 P78368 1/20 0.49
▸ CYP2C9 P11712 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C19 P33261 1/20 0.41
▸ USP30 Q70CQ3 1/20 0.41
▸ GSK3B P49841 1/20 0.40
▸ CYP2A6 P11509 1/20 0.38
▸ PIN1 Q13526 1/20 0.37
▸ PPARA Q07869 1/20 0.37
▸ PKN1 Q16512 1/20 0.36
▸ PKN2 Q16513 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL507628 0.85 PPARA (0.49) APPDYRK1ACSNK1DCSNK1G2CYP2A6
SCHEMBL28327150 0.80 APP (0.55) APPDYRK1ACSNK1DCSNK1G2CYP2C9
SCHEMBL6633096 0.80 DYRK1A (0.56) APPDYRK1ACSNK1DCSNK1G2CYP2C9
SCHEMBL2001976 0.80 APP (0.63) APPDYRK1ACYP2C9CYP3A4CYP2C19
SCHEMBL1032990 0.80 APP (0.55) APPDYRK1ACSNK1DCSNK1G2CYP2C9
SCHEMBL2032785 0.80 APP (0.55) APPDYRK1ACSNK1DCSNK1G2CYP2C9
SCHEMBL10274766 0.80 APP (0.55) APPDYRK1ACSNK1DCSNK1G2CYP2C9
SCHEMBL24265948 0.76 APP (0.51) APPDYRK1ACSNK1DCSNK1G2CYP2C9
SCHEMBL15481041 0.76 DYRK1A (0.52) APPDYRK1ACSNK1DCSNK1G2CYP2C9
SCHEMBL10220053 0.76 CSNK1D (0.58) APPDYRK1ACSNK1DCSNK1G2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636385-B2 Selective ligands for tau aggregates SENTONIX, INC. (US) 2026-05-26 — — US disclosed
EP-4387965-A2 ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS ChemoCentryx, Inc. (US) 2024-06-26 — — EP disclosed
US-12012403-B2 Aryl sulfonyl compounds as CCR6 inhibitors CHEMOCENTRYX, INC. (US) 2024-06-18 — — US disclosed
CN-118019735-A Arylsulfonyl compounds as CCR6 inhibitors 坎莫森特里克斯公司 2024-05-10 — — CN disclosed
WO-2023229375-A1 HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF 주식회사 엘지화학 2023-11-30 — — WO disclosed
US-20230125684-A1 Aryl Sulfonyl Compounds as CCR6 Inhibitors CHEMOCENTRYX, INC. 2023-04-27 — — US disclosed
WO-2023023534-A2 ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS CHEMOCENTRYX, INC. (US) 2023-02-23 — — WO disclosed
EP-3468977-B1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2021-07-21 — — EP disclosed
EP-3468977-B1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2021-07-21 — — EP disclosed
CN-108064223-B FXR (NR1H4) MODULATING COMPOUNDS CONTAINING HYDROXY GROUPS 吉利德科学公司 2021-06-01 — — CN disclosed
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist ELI LILLY AND COMPANY (US) 2012-02-02 — — US disclosed
CN-102329267-A 6-substituted 2,3,4, 5-tetrahydro-1H-benzo [d] aza as 5-HT2Creceptor agonists LILLY CO ELI 2012-01-25 — — CN disclosed
CN-102311387-A 6-substituted 2,3,4, 5-tetrahydro-1H-benzo [d] aza as 5-HT2Creceptor agonists LILLY CO ELI 2012-01-11 — — CN disclosed
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 — — US disclosed
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 — — US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 — — US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 — — US disclosed
CN-1934088-A As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * LILLY CO ELI (US) 2007-03-21 — — CN disclosed
EP-1720836-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2006-11-15 — — EP disclosed
WO-2005082859-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2005-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 APP 2423/4885DYRK1A 1266/4885CSNK1D 1487/4885
US-12636385-B2 Selective ligands for tau aggregates MAPT, PSEN2, PSEN1 APP 36/4885DYRK1A 3709/4885CSNK1D 419/4885
US-12012403-B2 Aryl sulfonyl compounds as CCR6 inhibitors CCR6, CCR1, CCR3 APP 4845/4885DYRK1A 4791/4885CSNK1D 1684/4885
US-20230125684-A1 Aryl Sulfonyl Compounds as CCR6 Inhibitors CCR6, CCR1, CCR3 APP 4845/4885DYRK1A 4791/4885CSNK1D 1684/4885
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist HTR2C, HTR4, HTR1A APP 3002/4885DYRK1A 1025/4885CSNK1D 1570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.